SPOTLIGHT -
During a press briefing held at the 4th COPHy congress in Budapest, Hungary, key opinion leaders discussed VMT and macular holes and how a new injectable drug could benefit patients. In this article, we will present the highlights of this meeting.
Exonate shares results from Phase Ib/IIa trial of EXN407 eye drops for DR and DME
In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407
COPHy 2024: Intraocular inflammation as a risk factor resulting from use of anti-complement agents for GA
Good news for patients: use of anti-complement therapies have caused the growth rate of GA lesions to decrease
Kiora publishes results from Phase 1 study demonstrating safety, tolerability and efficacy of KIO-101
Kiora also stated a Phase 2 trial of KIO-104 is expected to begin later this year
The “fourth dimension” of home monitoring
A longitudinal, AI-based approach to fluid quantification
AI models used to automate remote screening for diabetic retinopathy
The algorithms could provide major accessibility improvements and cost savings to underdeveloped regions
OCT retinal scans show the eye-kidney connection
The kidney and eye are structurally similar and the diseases of the organs may present via common pathways